Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathy Abbott

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Applied Neuropsychology. Child|May 19, 2016
Working Memory and NeurofeedbackEric YuLeung To, Kathy Abbott, Dale S Foster, et al.
Pharmacology & Therapeutics|March 4, 2021
Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosisMark J Turner, Kathy Abbott-Banner, David Y Thomas, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|December 22, 2021
Phosphodiesterase 8A Regulates CFTR Activity in Airway Epithelial CellsMark J Turner, Yukiko Sato, David Y Thomas, et al.
Arthritis and Rheumatism|March 1, 2007
RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositisKelly A Rouster-Stevens, Craig B Langman, Heather E Price, et al.
Pharmaceutical Research|January 6, 2022
Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE TechnologyDebra Tompson, Mark Whitaker, Rennan Pan, et al.
Arthritis and Rheumatism|September 30, 2006
Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammationLauren M Pachman, Arthur Veis, Stuart Stock, et al.
Pharmaceutical Research|June 17, 2021
Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772Debra J Tompson, Mark Whitaker, Rennan Pan, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|November 8, 2015
The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epitheliaMark J Turner, Elizabeth Matthes, Arnaud Billet, et al.
Clinical and Translational Science|September 9, 2024
Randomized, placebo-controlled study on the effects of intravenous GSK3858279 (anti-CCL17) on a battery of evoked pain tests in healthy participantsYvonne Boyle, Hemme J Hijma, Jamie Rees, et al.
BMJ Open Gastroenterology|August 14, 2021
A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitisKathy Weisel, Nicola Scott, Scott Berger, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Applied Neuropsychology. Child|May 19, 2016
Working Memory and NeurofeedbackEric YuLeung To, Kathy Abbott, Dale S Foster, et al.
Pharmacology & Therapeutics|March 4, 2021
Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosisMark J Turner, Kathy Abbott-Banner, David Y Thomas, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|December 22, 2021
Phosphodiesterase 8A Regulates CFTR Activity in Airway Epithelial CellsMark J Turner, Yukiko Sato, David Y Thomas, et al.
Arthritis and Rheumatism|March 1, 2007
RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositisKelly A Rouster-Stevens, Craig B Langman, Heather E Price, et al.
Pharmaceutical Research|January 6, 2022
Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE TechnologyDebra Tompson, Mark Whitaker, Rennan Pan, et al.
Arthritis and Rheumatism|September 30, 2006
Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammationLauren M Pachman, Arthur Veis, Stuart Stock, et al.
Pharmaceutical Research|June 17, 2021
Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772Debra J Tompson, Mark Whitaker, Rennan Pan, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|November 8, 2015
The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epitheliaMark J Turner, Elizabeth Matthes, Arnaud Billet, et al.
Clinical and Translational Science|September 9, 2024
Randomized, placebo-controlled study on the effects of intravenous GSK3858279 (anti-CCL17) on a battery of evoked pain tests in healthy participantsYvonne Boyle, Hemme J Hijma, Jamie Rees, et al.
BMJ Open Gastroenterology|August 14, 2021
A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitisKathy Weisel, Nicola Scott, Scott Berger, et al.
Pageof 2